Document is current
Any future updates will be listed below
-
Authors
Chesnaye, Nicholas C. http://orcid.org/0000-0003-4883-9174
Ortiz, Alberto http://orcid.org/0000-0002-9805-9523
Zoccali, Carmine
Stel, Vianda S.
Jager, Kitty J. http://orcid.org/0000-0003-0444-8569
- License Information
-
More Information
Article History
Accepted: 13 June 2024
First Online: 18 July 2024
Competing interests
: A.O. has received grants from Sanofi and consultancy or speaker fees or travel support from Adviccene, Alexion, Astellas, Astrazeneca, Amicus, Amgen, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi–Genzyme, Menarini, Mundipharma, Kyowa Kirin, Lilly, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma. He is Director of the Catedra UAM-AstraZeneca of chronic kidney disease and electrolytes and he has stock in Telara Farma.
